Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM

Diabetes

Volumn 45, Issue 3 SUPPL., 1996, Pages 881-885

  Ofei, F ^a   Hurel, S ^a   Newkirk, J ^a   Sopwith, M ^a   Taylor, R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CATECHOLAMINE; FATTY ACID; GLUCAGON; INSULIN; NEUTRALIZING ANTIBODY; ORAL ANTIDIABETIC AGENT; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENETIC ENGINEERING; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029906375     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.7.881     Document Type: Article

References (0)